Management of Non-response and Loss of Response to Anti-tumor Necrosis Factor Therapy in Inflammatory Bowel Disease

Anti-tumor necrosis factor (anti-TNF) therapy has been successfully used as first-line biologic treatment for moderate-to-severe inflammatory bowel disease (IBD), in both “step-up” and “top-down” approaches, and has become a cornerstone of IBD management. However, in a proportion of patients the eff...

Descripción completa

Detalles Bibliográficos
Autores principales: Marsal, Jan, Barreiro-de Acosta, Manuel, Blumenstein, Irina, Cappello, Maria, Bazin, Thomas, Sebastian, Shaji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9241563/
https://www.ncbi.nlm.nih.gov/pubmed/35783628
http://dx.doi.org/10.3389/fmed.2022.897936

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9241563/
https://www.ncbi.nlm.nih.gov/pubmed/35783628
http://dx.doi.org/10.3389/fmed.2022.897936

Ejemplares similares